Mr. Hayim Raclaw reports

ALZAI HEALTH CORP. ANNOUNCES VALIDATION OF ITS AI-DRIVEN ALZHEIMERS DISEASE RISK SCREENING SOLUTION ON LARGE-SCALE U.S. PATIENT DATA

Alzai Health Corp. has validated its proprietary artificial intelligence-driven Alzheimer's disease risk identification models using a large-scale United States longitudinal health care data set, representing a significant milestone in the company's potential U.S. commercialization.

The validation demonstrated that Alzai's risk-stratification models achieved performance on par with previous validation studies conducted using Israeli health care data, supporting management's belief that the company's technology may have the potential to perform across different health care systems and patient populations.

The validation utilized real-world longitudinal health care data on more than 1.1 million U.S. patients. The data set contained approximately 38 million common blood chemistry laboratory test results and over three million standard chronic disease diagnostic records collected through routine care representing over 100 million clinical data points.

The U.S. health care data set was licensed from HealthVerity, a leading provider of real-world health care data in the United States, and was used to evaluate Alzai's proprietary artificial intelligence solution across multiple prediction horizons and varying lengths of longitudinal patient history. The validation included blood-test-only, chronic disease diagnoses only and combined blood-test-data-and-chronic-disease-diagnoses models. Alzai utilizes ubiquitous and routine clinical information and basic patient demographics in order to deliver a population-level risk screening solution. HealthVerity did not participate in the development of Alzai's artificial intelligence models, the validation methodology, the analysis of results or the conclusions presented by the company, and did not verify, endorse or independently validate the company's results or conclusions. The validation was based on a licensed historical real-world data set and specific model assumptions and methodologies, and results may not be replicated in prospective studies, other data sets, other patient populations or real-world clinical implementation.

The validation supports the scalability of Alzai's Solution across multiple health care environments and represents an important milestone as the company moves toward potential commercialization within the United States. Alzai believes that demonstrating consistent model performance across independent health care data sets strengthens the potential applicability of its technology within U.S. health care systems, pharmaceutical research and population health initiatives. Alzai's solution is intended to support disease risk identification and is not intended to diagnose Alzheimer's disease or replace clinical judgment.

"Alzheimer's has been a rapidly growing problem, and this health care reality is compounded by the fact that the vast majority of patients are diagnosed too late for the most effective treatments and most people at elevated risk remain unidentified for preventative care. Validating our technology using a large-scale, real-world U.S. health care data represents an important milestone for Alzai and further demonstrates the robustness and scalability of our non-invasive disease risk screening solution," said Hayim Raclaw, chief executive officer of Alzai Health.

"One of the most important challenges for any artificial intelligence model is demonstrating that it performs consistently beyond the environment in which it was originally developed. Achieving comparable validation results using a large U.S. real-world data set reinforces the generalizability of our technology and delivers credibility for responsible healthcare users of Alzai in the United States. We believe scalable, non-invasive disease risk stratification solutions have the potential to become a tool for health care providers, life sciences organizations and pharmaceutical companies focused on earlier identification of patients with disease and patients at elevated risk of developing disease, all in service of more efficient and effective patient engagement," said Dr. Amir Glik, chief medical officer of Alzai Health.

About Alzai Health Corp.

Alzai Health is a health care technology company developing non-invasive, artificial-intelligence-driven disease risk identification solutions using routine health care data. The company's proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. Alzai's technology has been validated on large-scale health care data sets and is designed for integration into existing health care infrastructure, including electronic medical record systems, cloud-based environments and enterprise health care platforms.

We seek Safe Harbor.